Real science, real interactions, real time

Don’t miss out on the latest developments in biophysical characterization.

Be inspired by the latest scientific research.
Engage with leading scientists.
Learn tips and techniques in biophysical characterization.

DiPIA attracts delegates and speakers from around the world. Interact with experts from academia and industry who will be sharing their work in areas from basic research to quality control using Biacore systems.

Learn more

Hear what our customers have to say…

Ite Laird-Offringa
Associate Prof. of Surgery
University of Southern California


Dominico Vigil
Biophysics Scientist
Agios


Shashank Sunkara
Research Associate
Momenta


Vishal Kamat
Staff Scientist
Regeneron


Conference topics

Characterization of biotherapeutics

The characterization of biotherapeutics was one of the seminal applications of surface plasmon resonance (SPR) when it was first commercialized in the early 1990’s. Hear the latest trends and applications.


Assessment of critical quality attributes of biotherapeutics

Current trends in QC applications of SPR with the objective of exploring best practices to meet current regulatory expectations.

Low molecular weight drug discovery and characterization

Biacore systems can be employed in drug discovery from the early stages of fragment-based drug discovery and hit screening through to detailed characterization of novel lead compounds.


From basic research to advanced applications

Scientists presenting their latest successes from the lab.


Tutorials

Join our pre-conference tutorials offered at no extra cost on Sunday, June 17, 2018.

  • Good, Bad, or Ugly? Understanding what the data is telling you
  • Get the most out of your data: current data analysis approaches
  • Best practices for working with low molecular weight compounds
  • Hunting high or low: choosing the appropriate immobilization strategy


Workshops

Each 90 min session will provide educational and practical information on a range of application and methodology-related topics connected to Biacore systems.

  • Small molecules as therapeutics: from structure-activity relationship to clinical trials
  • SPR-based assays for comparability and potency assessment
  • Driving forward drug discovery with binding kinetics
  • Use of SPR in process development of biotherapeutics


Speak at DiPIA

DiPIA 2018 is an excellent opportunity to showcase your research within the biophysical characterization community. To be considered for a presentation, please submit an abstract in one of the following areas:

  • Characterization of biotherapeutics
  • Assessment of critical quality attributes of biotherapeutics
  • Low molecular weight drug discovery and characterization
  • From basic research to advanced applications


Abstracts must describe original work and should be no more than 500 words long. The deadline for submitting your abstract is January 2, 2018.

ABSTRACT SUBMISSION CLOSED

 


DiPIA poster session

Present a scientific poster

Share your new research by presenting a poster at DiPIA 2018. All selected posters are displayed in the exhibit & poster hall area for the duration of conference.

Poster abstracts should be no more than 500 words and must describe original work; they should contain the author’s name, affiliation, email address, topic, and description.

Please note that all poster presenters must be registered attendees. The deadline for submitting your abstract is MAY 1, 2018.


ABSTRACT SUBMISSION CLOSED


Keynote speakers

Characterization of biotherapeutics


Ute Jucknischke
Roche Diagnostics GmbH,
Penzberg, Germany

Assessment of critical quality attributes of biotherapeutics


Sumana Chandramouli, Ph.D.
GlaxoSmithKline,
Rockville, MD, USA

Low molecular weight drug discovery and characterization


Sanjay Panchal, Ph.D.
AbbVie,
North Chicago, IL, USA

From basic research to advanced applications


Betsy Yakes, Ph.D.
U.S. Food and Drug Administration,
College Park, MD, USA


Main session speakers


Lauren Ely, Ph.D.
Pfizer/Centers for
Therapeutic Innovation,
San Francisco, CA, USA

Juhi Juneja, Ph.D.
Bristol-Myers Squibb,
Waltham, MA, USA

Siok Wan Gan, Ph.D.
Chugai Pharmabody Research Pte. Ltd.,
Singapore

Wei Wang, Ph.D.
Amgen,
Thousand Oaks, CA, USA

Kevin Lindquist, M.S.
Pfizer,
South San Francisco, CA, USA

Jianhong Ma, Ph.D.
GlaxoSmithKline,
King of Prussia, PA, USA

Daniel Malashock, Ph.D.
Merck,
Palo Alto, CA, USA

Markus Kuegler, Ph.D.
Boehringer Ingelheim,
Biberach an der Riss, Germany

Graeme Anderson, Ph.D.
Sartorius Stedim BioOutsource,
Glasgow, UK

LeeAnn Machiesky, M.S.
MedImmune,
Gaithersburg, MD, USA

Peter Coombs, Ph.D.
LifeArc,
Stevenage, UK

Hyun Lee, Ph.D.
University of Illinois at Chicago,
Chicago, IL, USA

Kristin Hamman, M.S.
Syros Pharmaceuticals,
Cambridge, MA, USA

Bhamini Vaidialingam
Agios Pharmaceuticals,
Cambridge, MA, USA

Göran Dahl, Ph.D.
AstraZeneca,
Mölndal, Sweden

Robert Stahelin, Ph.D.
Purdue University,
West Lafayette, IN, USA

Frantz Jean-Francois, Ph.D.
National Institutes of Health/
National Cancer Institute,
Fredrick, MD, USA

Claire Harris, Ph.D.
Newcastle University,
Newcastle upon Tyne, UK


Workshop session speakers


Michael Willcox, Ph.D.
Eurofins,
Munich, Germany

Giordana Bruni, Ph.D.
Merck Serono,
Roma, Italy

Robert Karlsson
EDPAR,
Uppsala, Sweden

Linnéa Nygren Babol, Ph.D.
GE Healthcare,
Uppsala, Sweden

Markus Sack
Fraunhofer Institute for Molecular Biology and Applied Ecology,
Alsdorf, Germany

Xiangdan Wang, Ph.D.
Genentech,
South San Francisco, California, USA

Matthias Frech, Ph.D.
Merck KGaA,
Darmstadt, Germany

Joost Uitdehaag, Ph.D.
Netherlands Translational Research Center,
Oss, The Netherlands

Philip Schwartz, Ph.D.
Merck,
South San Francisco, CA, USA

Olof Karlsson, Ph.D.
GE Healthcare,
Uppsala, Sweden

Janice Villali, Ph.D.
Sanofi Genzyme,
Waltham, MA, USA

Göran Dahl, Ph.D.
AstraZeneca,
Mölndal, Sweden

Tutorial session speakers

Good, Bad, or Ugly? Understanding what the data is telling you


Michael Murphy, Ph.D.
GE Healthcare,
Marlborough, MA, USA

Good, Bad, or Ugly? Understanding what the data is telling you


Paul Belcher, Ph.D.
GE Healthcare,
Marlborough, MA, USA

Get the most out of your data: current data analysis approaches


Olof Karlsson, Ph.D.
GE Healthcare,
Uppsala, Sweden


Best practices for working with low molecular weight compounds


Cynthia Shuman, Ph.D.
GE Healthcare,
Marlborough, MA, USA

Hunting high or low: choosing the appropriate immobilization strategy


Anja Drescher, Ph.D.
GE Healthcare,
Munich, Germany

Agenda Download full agenda

Registration Open

10:00 AM – 6:00 PM

Poster Drop-off

10:00 AM – 4:00 PM

Lunch

12:00 PM – 12:45 PM

Good, Bad, or Ugly? Understanding what the data is telling you

Michael Murphy and Paul Belcher, GE Healthcare, Marlborough, MA, USA

Tutorial Session I
12:45 PM – 1:45 PM

Get the most out of your data: current data analysis approaches

Olof Karlsson, GE Healthcare, Uppsala, Sweden

Tutorial Session II
1:45 PM – 2:45 PM

Coffee Break

2:45 PM – 3:15 PM
Tutorial Session III – parallel sessions

Best practices for working with low molecular weight compounds

Cynthia Shuman, GE Healthcare, Marlborough, MA, USA

Tutorial Session III - (i)
3:15 PM – 4:15 PM

Hunting high or low: choosing the appropriate immobilization strategy

Anja Drescher, GE Healthcare, Munich, Germany

Tutorial Session III - (ii)
3:15 PM – 4:15 PM

Bio-Break

4:15 PM – 4:30 PM
Workshop Session I – parallel sessions

Small molecules as therapeutics: from structure-activity relationship to clinical trials

Binding kinetics - a key parameter for rational drug design

Olof Karlsson, GE Healthcare, Uppsala, Sweden

Developing a SPR strategy for small molecules that disrupt a protein: protein interaction

Janice Villali, Sanofi Genzyme, Waltham, MA, USA

SPR in late stage pre-clinical development

Göran Dahl, AstraZeneca, Mölndal, Sweden

Workshop Session I - (i)
4:30 PM – 6:00 PM

SPR-based assays for comparability and potency assessment

A closer look at Fc receptors and their binding properties to therapeutic antibodies

Mike Willcox, Eurofins, Munich, Germany

A new magnifying glass for CQA monitoring

Giordana Bruni, Merck Serono, Rome, Italy

Ligand binding for assessment of similarity and relative potency– perspectives of assay design and data analysis

Robert Karlsson, EDPAR, Uppsala, Sweden

Workshop Session I - (ii)
4:30 PM – 6:00 PM

Welcome Reception

Scott Ripley, GE Healthcare, Uppsala, Sweden

7:30 PM

Registration Open

7:00 AM

Breakfast

7:00 AM – 8:00 AM

Foreword

Paul Belcher, GE Healthcare, Marlborough, MA, USA

8:00 AM – 8:15 AM
Main Session I

Characterization of biotherapeutics I

Displacement of BMP9 pro-domains after receptor binding discovered via SPR

Ute Jucknischke, Roche Diagnostics GmbH, Penzberg, Germany

SPR Informs Selection of Lead Therapeutic Candidates with Desirable Binding Properties

Juhi Juneja, Bristol-Myers Squibb, Waltham, MA, USA

Development of a factor XIa-specific IgG and reversal reagent for thrombotic disease: a race against factor IX!

Lauren Ely, Pfizer/Centers for Therapeutic Innovation, San Francisco, CA, USA

Main Session I
8:15 AM – 10:00 AM
Keynote

Poster Session I & Exhibition/Coffee Break

10:00 AM – 10:30 AM
Main Session I

Low molecular weight drug discovery and characterization I

Profiling of Compound Kinetics in Hit to Lead Drug Discovery: EED as a case study

Sanjay Panchal, AbbVie, Chicago, IL, USA

Fragment-Based Target Screening for Anti-Bacterials

Peter Coombs, LifeArc, Stevenage, UK

Identification of novel small molecule inhibitors against NS2B/NS3 serine protease from Zika virus

Hyun Lee, University of Illinois at Chicago, Chicago, IL, USA

Main Session I
10:30 AM – 12:30 PM
Keynote

Lunch

12:30 PM – 1:30 PM
Workshop Session II – parallel sessions

SPR-based assays for comparability and potency assessment

A closer look at Fc receptors and their binding properties to therapeutic antibodies

Mike Willcox, Eurofins, Munich, Germany

A new magnifying glass for CQA monitoring

Giordana Bruni, Merck Serono, Rome, Italy

Ligand binding for assessment of similarity and relative potency– perspectives of assay design and data analysis

Robert Karlsson, EDPAR, Uppsala, Sweden

Workshop Session II - (i)
1:30 PM – 3:00 PM

Driving forward drug discovery with binding kinetics

Driving Forward Drug Discovery with Binding Kinetics

Matthias Frech, Merck KGaA, Darmstadt, Germany

Optimization focused on target residence time results in TTK inhibitors with potent anti-proliferative activity

Joost Uitdehaag, Netherlands Translational Research Center, Oss, The Netherlands

Commitment to Covalency: Using Biacore to Understand and Evaluate the Biochemical Potency of Highly Optimized Irreversible Inhibitors

Philip Schwartz, Merck, South San Francisco, CA, USA

Workshop Session II - (ii)
1:30 PM – 3:00 PM

Poster Session II & Exhibition/Coffee Break

3:00 PM – 4:30 PM
Main Session III

Assessment of critical quality attributes of biotherapeutics I

SPR in early discovery and characterization of vaccine antigens

Sumana Chandramouli, GlaxoSmithKline, Rockville, MD, USA

The Importance of Rmax for Activity Assessment

Daniel Malashock, Merck, Palo Alto, CA, USA

SPR analytics in the Development of Biopharmaceuticals

Markus Kuegler, Boehringer Ingelheim, Biberach an der Riss, Germany

Main Session III
4:30 PM – 6:30 PM
Keynote

Dinner on your own

6:30 PM

Registration Open

7:00 AM

Breakfast & Roundtables

7:00 AM – 8:00 AM

Opening Remarks

Tim Fagge, GE Healthcare, Amersham Place, Little Chalfont, UK

8:10 AM – 8:15 AM
Main Session II

Low molecular weight drug discovery and characterization II

Highly sensitive binding kinetics of CDK7/cyclin H by small molecules

Kristin Hamman, Syros Pharmaceuticals, Cambridge, MA, USA

Probing molecular mechanisms of metabolic enzymes using A-B-A injection method

Bhamini Vaidialingam, Agios Pharmaceuticals, Cambridge, MA, USA

SPR at AstraZeneca: Beyond affinity and kinetics

Göran Dahl, AstraZeneca, Mölndal, Sweden

Main Session II
8:15 AM – 10:00 AM

Coffee Break & Exhibition

10:00 AM – 10:30 AM
Main Session II

Characterization of biotherapeutics II

Application of Biacore and AKTA instrumentation to the characterization and production of bispecific IgG from a common-light chain synthetic human antibody library

Kevin Lindquist, Pfizer, South San Francisco, CA, USA

Glycosylation Profiling of Biotherapeutics using Lectin Binding by SPR

Wei Wang, Amgen, Thousand Oaks, CA, USA

Application of Biacore in pH dependent Ab screening

Siok Wan Gan, Chugai Pharmabody Research Pte. Ltd., Singapore

Main Session II
10:30 AM – 12:30 PM

Lunch

12:30 PM – 1:30 PM

Tutorial: Get the most out of your data: current data analysis approaches

Olof Karlsson, GE Healthcare, Uppsala, Sweden

12:50 PM – 1:25 PM
Main Session III

Assessment of critical quality attributes of biotherapeutics II

Use of SPR-based Kinetic Assays for CQA assessment of Biotherapeutics

LeeAnn Machiesky, MedImmune, Gaithersburg, MD, USA

Generating a Quality Attribute Profile for Antibody-Based Biosimilars: Assessing Differences in Fc-Associated Effector Functions

Graeme Anderson, Sartorius Stedim BioOutsource, Glasgow, UK

Surface Plasmon Resonance Technology for Biopharmaceutical Drug Release and Stability Testing: Method Development, Transfer and Validation

Jianhong Ma, GlaxoSmithKline, King of Prussia, PA, USA

Main Session III
1:30 PM – 3:15 PM

Poster Session III & Exhibition/Coffee Break

3:15 PM – 4:30 PM
Workshop Session III

Use of SPR in process development of biotherapeutics

Biacore Adenovirus quantification

Linnéa Nygren Babol, GE Healthcare, Uppsala, Sweden

Early-stage SPR assays for recombinant subunit vaccine discovery and process development

Markus Sack, Fraunhofer Institute for Molecular Biology and Applied Ecology, Aachen, Germany

Molecular Interaction Characterization during Early Development to Enable IND Filing

Xiangdan Wang, Genentech, South San Francisco, CA, USA

Workshop Session III - (i)
4:30 PM – 6:00 PM

Small molecules as therapeutics: from structure-activity relationship to clinical trials

Binding kinetics - a key parameter for rational drug design

Olof Karlsson, GE Healthcare, Uppsala, Sweden

Developing a SPR strategy for small molecules that disrupt a protein: protein interaction

Janice Villali, Sanofi Genzyme, Waltham, MA, USA

SPR in late stage pre-clinical development

Göran Dahl, AstraZeneca, Mölndal, Sweden

Workshop Session III - (ii)
4:30 PM – 6:00 PM

Gala Dinner and Poster Awards

7:00 PM

Registration Open

7:30 AM

Breakfast

7:30 AM – 8:30 AM

Opening Remarks

Tim Fagge, GE Healthcare, Amersham Place, Little Chalfont, UK

8:30 AM – 8:40 AM

Poster award winner presentations

8:40 AM – 9:20 AM

Intro to main session

9:20 AM – 9:30 AM
Main Session IV

From basic research to advanced applications I

On-chip amplification of the complement cascade; functional assays to dissect disease mechanism and test therapeutics

Claire Harris, Newcastle University, Newcastle upon Tyne, UK

Main Session IV
9:30 AM – 10:00 AM

Coffee Break & Exhibition

10:00 AM – 10:30 AM
Main Session IV

From basic research to advanced applications II

Quantification of Lipid-Protein Interactions in the Assembly and Budding of Filoviruses Using Biacore Technology

Robert Stahelin, Purdue University, West Lafayette, IN, USA

Protein-Lipid interaction characterization via SPR

Frantz Jean-Francois, National Institutes of Health/National Cancer Institute, Fredrick, MD, USA

Tracking toxins: SPR biosensors for antibody development, screening seafood, and biomarker assays

Betsy Yakes, U.S. Food and Drug Administration, College Park, MD, USA

Main Session IV
10:30 AM – 12:15 PM






Keynote

Closing Remarks

Paul Belcher, GE Healthcare, Marlborough, MA, USA

12:15 PM – 12:30 PM

Lunch

12:30 PM – 1:30 PM

Registration fees



DELEGATE

3 registrations qualify for 10% discount


$950




Biacore club MEMBER





$850




ONE DAY PASS

June 17 - Includes welcome reception
June 18 - Scientific conference entry only
June 19 - Excludes gala dinner

$400

Venue information

Visit hotel website

DiPIA 2018 venue:

Revere Hotel
Boston Common
200 Stuart Street
Boston, MA 02116
Tel: (617) 482-1800

Attendees are encouraged to take advantage of our discounted hotel rooms at the Revere Hotel, with rooms starting at $279/night. If you need to make a reservation please contact Amanda Young, amanda.young@ge.com. If you need to make changes to your existing reservation please call (617) 457-2683.

View in google maps

NovAliX conference

NovAliX Biophysics in Drug Discovery 2018

Don’t miss out–Register for DiPIA and get 15% off NovAliX conference

The 2018 edition of the NovAliX Conference will bring together biophysicists and medicinal chemists to improve the synergy between their disciplines to deliver better drugs on shorter timelines.

The scientific program for NovAliX will include:

  • Featured presentation: Cryo-EM
  • Membrane proteins
  • Protein-protein interactions
  • Biotherapeutics
  • Target engagement
  • Hot topics

The Keynote Lecture will be delivered by Professor Martin Karplus (Nobel Prize in Chemistry 2013).

The scientific program will be complemented by short exhibitor presentations, a poster session and a commercial exhibition.

Register

>